KIDS vs. NVCR, LMAT, EYE, ENOV, CNMD, TNDM, SSII, CDRE, AORT, and LQDA
Should you be buying OrthoPediatrics stock or one of its competitors? The main competitors of OrthoPediatrics include NovoCure (NVCR), LeMaitre Vascular (LMAT), National Vision (EYE), Enovis (ENOV), CONMED (CNMD), Tandem Diabetes Care (TNDM), SS Innovations International (SSII), Cadre (CDRE), Artivion (AORT), and Liquidia Technologies (LQDA). These companies are all part of the "medical equipment" industry.
OrthoPediatrics vs. Its Competitors
OrthoPediatrics (NASDAQ:KIDS) and NovoCure (NASDAQ:NVCR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment and analyst recommendations.
OrthoPediatrics currently has a consensus price target of $35.83, suggesting a potential upside of 59.51%. NovoCure has a consensus price target of $32.83, suggesting a potential upside of 85.45%. Given NovoCure's higher probable upside, analysts clearly believe NovoCure is more favorable than OrthoPediatrics.
OrthoPediatrics has a net margin of -19.15% compared to NovoCure's net margin of -26.41%. OrthoPediatrics' return on equity of -7.03% beat NovoCure's return on equity.
In the previous week, NovoCure had 5 more articles in the media than OrthoPediatrics. MarketBeat recorded 7 mentions for NovoCure and 2 mentions for OrthoPediatrics. OrthoPediatrics' average media sentiment score of 0.40 beat NovoCure's score of 0.39 indicating that OrthoPediatrics is being referred to more favorably in the media.
OrthoPediatrics has higher earnings, but lower revenue than NovoCure. OrthoPediatrics is trading at a lower price-to-earnings ratio than NovoCure, indicating that it is currently the more affordable of the two stocks.
69.1% of OrthoPediatrics shares are owned by institutional investors. Comparatively, 84.6% of NovoCure shares are owned by institutional investors. 32.7% of OrthoPediatrics shares are owned by insiders. Comparatively, 5.5% of NovoCure shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
OrthoPediatrics has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500. Comparatively, NovoCure has a beta of 0.72, suggesting that its stock price is 28% less volatile than the S&P 500.
Summary
OrthoPediatrics beats NovoCure on 9 of the 16 factors compared between the two stocks.
Get OrthoPediatrics News Delivered to You Automatically
Sign up to receive the latest news and ratings for KIDS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding KIDS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
OrthoPediatrics Competitors List
Related Companies and Tools
This page (NASDAQ:KIDS) was last updated on 7/5/2025 by MarketBeat.com Staff
